JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2011, 60(6):283-289

Analytical profile of 1-[3-(3-propoxyphenylcarbamoyloxy)-2-hydroxypropyl]-4-(3-tri-fluoromethylphenyl)piperazinium chloride

Ivan Malík
Univerzita Komenského Bratislava, Farmaceutická fakulta, Katedra farmaceutickej chémie

The purpose of the paper was the completing of the experimentally estimated physicochemical descriptors spectrum of 1-[3-(3-propoxyphenylcarbamoyloxy)-2-hydroxypropyl]-4-(3-trifluoromethylphenyl)piperazinium chloride (labelled as 8e), an effective, highly lipophilic compound against non-tuberculous M. kansasii My 235/80. The identity of the structure 8e was verified by 1H- and 13C-NMR spectral data, IR spectrometry and by elemental analysis as well. The readout from mass spectrometry confirmed an existence of the molecular ion [M + H+]+. The purity of the evaluated compound 8e was checked by absorption thin-layer chromatography, the stability of its aqueous and methanolic solutions was investigated under UV/VIS light. The values of some physicochemical descriptors assigned to 8e, which had been previously published (pKa, log Pexp), were correlated with the constants associated with some antimycobacterially active molecules which are commonly used in therapeutical practice (isoniazid, pyrazinanide, para-aminosalicylic acid, ethionamide, streptomycine). For the content determination of the molecule of 8e, RP-HPLC (reversed-phase HPLC) method with an internal standard and UV/VIS spectrophotometry at the wavelength of 238 nm (aqueous medium) and at 244 nm (methanolic medium) were used.

Keywords: non-tuberculous mycobacteria; analytical evaluation; phenylcarbamates; N-phenylpiperazine

Received: July 18, 2011; Accepted: August 22, 2011; Published: June 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Malík I. Analytical profile of 1-[3-(3-propoxyphenylcarbamoyloxy)-2-hydroxypropyl]-4-(3-tri-fluoromethylphenyl)piperazinium chloride. Čes. slov. farm. 2011;60(6):283-289.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chou, Y.-H., Hsu, M.-S., Sheng, W.-H., Chang, S.-Ch.: Disseminated Mycobacterium kansasii infection associated with hemophagocytic syndrome. Int. J. Infect. Dis. 2010; 14, 262-264. Go to original source... Go to PubMed...
    2. McGrath, E. E., Anderson, P. B.: The therapeutic approach to non-tuberculous mycobacterial infection of the lung. Pulm. Pharmacol. Ther. 2010; 23, 389-396. Go to original source... Go to PubMed...
    3. McGrath, E. E., Anderson, P. B.: Increased prevalence of non-tuberculous mycobacteria infection. Lancet 2007; 370, 28. Go to original source... Go to PubMed...
    4. Taillard, C., Greub, G., Weber, R., Pfyffer, G. E., Bodmer, T., Zimmerli, S., Frei, R., Bassetti, S., Rohner, P., Piffaretti, J. C., Bernasconi, E., Bille, J., Telenti, A., Prod'hom, G.: Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey. J. Clin. Microbiol. 2003; 41, 1240-1244. Go to original source... Go to PubMed...
    5. Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, Ch., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., Iseman, M., Olivier, K., Ruoss, S., von Reyn, C. F., Wallace, Jr., R. J., Winthrop, K.: An official ATS/IDSA statement: Diagnosis and treatment and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 2007; 175, 367-416. Go to original source... Go to PubMed...
    6. Campo, R. E., Campo, C. E.: Mycobacterium kansasii disease in patients infected with human immunodefiency virus. Clin. Infect. Dis. 1997; 24, 1233-1238. Go to original source... Go to PubMed...
    7. Arend, S. M., Cerdá de Palou, E., de Haas, P., Janssen, R., Hoeve M. A., Verhard, E. M., Ottenhoff, T. H., van Soolingen, D., van Dissel, J. T.: Pneumonia caused by Mycobacterium kansasii in a series of patients without recognised immune defect. Clin. Microbiol. Infect. 2004; 10, 738-748. Go to original source... Go to PubMed...
    8. Tateishi, Y., Hirayama, Y., Ozeki, Y., Nishiuchi, Y., Yoshimura, M., Kang, J., Shibata, A., Hirata, K., Kitada, S., Maekura, R., Ogura, H., Kobayashi, K., Matsumoto, S.: Virulence of Mycobacterium avium complex strains isolated from immunocompetent patients. Microbial Pathogenesis 2009; 46, 6-12. Go to original source... Go to PubMed...
    9. Shen, M.-Ch., Shin-Jung Lee, S., Huang, T.-S., Liu, Y.-Ch.: Clinical significance of isolation of Mycobacterium avium complex from respiratory specimens. J. Formos. Med. Assoc. 2010; 109, 517-523. Go to original source... Go to PubMed...
    10. Waisser, K., Doležal, R., Čižmárik, J., Malík, I., Kaustová, J.: The antimycobacterial derivatives against potential pathogenic strains: 2-Hydroxy-3-(4-phenylpiperazin-1-yl)-propylphenylcarbamates. Sci. Pharm. 2007; 75, 55-61. Go to original source...
    11. Waisser, K., Doležal, R., Čižmárik, J., Malík, I., Kaustová, J.: The potential antituberculotics of the series of 2-hydroxy-2-(4-phenylpiperazin-1-yl)-propylphenyl-carbamates. Folia Pharm. Univ. Carol. 2007; 35-36, 45-48.
    12. Ruffolo, R. R., Feuerstein, G. Z.: Pharmacology of carvedilol: rationale for use in ypertension, coronary artery disease, and congestive heart failure. Cardiovasc. Drugs Ther. 1997; 11(Suppl. 1), 247-256. Go to original source... Go to PubMed...
    13. Farthing, M. J. G., Alstead, E. M., Abrams, S. M. L., Haug, G., Johnston, A., Hermann, R., Niebch, G., Ruus, P., Molz, K. H., Turner, P.: Pharmacokinetics of naftopidil, a ovel antihypertensive drug, in patients with hepatic dysfunction. Postgrad. Med. J. 1994; 70, 363-366. Go to original source... Go to PubMed...
    14. Malík, I., Sedlárová, E., Csöllei, J., Andriamainty, F., Kurfürst, P., Vančo, J.: Synthesis, spectral description, and lipophilicity parameters determination of henylcarbamic acid derivatives with integrated N-phenylpiperazine moiety in the structure. Chem. pap. 2006; 60, 42-47. Go to original source...
    15. Malík, I., Sedlárová, E., Čižmárik, J., Andriamainty, F., Csöllei, J.: Štúdium fyzikálno-chemických vlastností derivátov kyseliny 2-, 3-, 4-alkoxyfenylkarbámovej s ázickou časťou tvorenou substituovaným N-fenylpiperazínom. Čes. slov. Farm. 2005; 54, 235-239.
    16. European Pharmacopoeia, 6th Ed. European Directorate for the Quality of Medicines and HealthCare (EDQM), Council of Europe, Strasbourg: Druckerei C.H. Beck 2007; s. 5.
    17. Sedlárová, E., Malík, I., Andriamainty, F., Kečkéšová, S., Csöllei, J.: Štúdium lipofility derivátov kyseliny fenylkarbámovej s bázickou časťou tvorenou substituovaným N-fenylpiperazínom. Farm. Obzor 2007; 74, 86-90.
    18. Malík, I., Andriamainty, F., Sedlárová, E., Čižmárik, J., Gališinová, J., Mokrý, P., Csöllei, J., Karlovská, J., Lukáč, M.: Analytické hodnotenie mono[{3-[4-(2-etoxyetoxy)-benzoyloxy]-2-hydroxypro- pyl}-izopropylamónium]fumarátu. Čes. slov. Farm. 2011; 60, 84-93.
    19. Sedlárová, E., Malík, I., Csöllei, J., Andriamainty, F.: Analytické hodnotenie 1-(4-fluórfenyl)-4-[3-(3-propoxyfenylkarbamoyloxy)-2-hydroxypropyl]piperazíniumchloridu (látka 6f). Čes. slov. Farm. 2005; 54, 270-274.
    20. Silverstein, R. M., Webster, F. X., Kiemle, D. J.: Spectrometric Identification of Organic Compounds. 7th Ed. New York, London, Sydney, Toronto: John Wiley and Sons 2005; 512 s.
    21. Herbert, Ch. G., Johnstone, R. A. W.: Mass Spectrometry Basics. Boca Raton, London, New York, Washington: CRC Press 2003; 474 s.
    22. Lemke, T. L., Williams, D. A., Roche, V. F., Zito, S. W.: Foye's Principles of Medicinal Chemistry. 6th Ed. Baltimore: Lippincott Williams & Wilkins, a Wolters Kluwer business 2008; 1377 s.
    23. Liu, J., Barry, C. E., Nikaido, H.: Cell wall: physical structure and permeability. In: Ratledge, C., Dale, J. eds. Mycobacteria, molecular biology and virulence. Oxford: Blackwell Science 1992.
    24. TB Alliance: Isoniazid. Tuberculosis 2008; 88, 112-116. Go to original source... Go to PubMed...
    25. TB Alliance: Pyrazinamide. Tuberculosis 2008; 88, 141-144. Go to original source... Go to PubMed...
    26. TB Alliance: Para-aminosalicylic acid. Tuberculosis 2008; 88, 137-138. Go to original source... Go to PubMed...
    27. TB Alliance: Ethionamide. Tuberculosis 2008; 88, 106-108. Go to original source... Go to PubMed...
    28. TB Alliance.: Streptomycin. Tuberculosis 2008; 88, 162-163. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.